GeneSet Title
Tier IV
Mouse
59 Genes
GS410668
LABEL: Striatal cis-eQTLs assoc. rs51237371 for OXY-induced locomotor in B6JxB6NJ F2 cross_pvalueDESCRIPTION: Cis-eQTLs associated with peak distal chromosome 1 marker for oxycodone (OXY)-induced locomotor activity (rs51237371; 181,318,003 bp). We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. Analysis was conducted using limma with default TMM normalization and VOOM transformation (Law et al. 2014; Ritchie et al. 2015). To account for the presence of replicates of each sample in the data, we used the duplicateCorrelation() function to estimate the within-sample correlation which we then included in the lmFit() function. An ANOVA test was conducted for gene expression, with Genotype as a fixed effect and Sex as a covariate. Gene-level tests were conducted using the Likelihood Ratio test. A false discovery rate of 5% was employed as the cut-off for statistical significance (Benjamini & Hochberg 1995). From supplementary table S4.
Tier IV
Mouse
59 Genes
GS410669
LABEL: Striatal cis-eQTLs assoc. rs51237371 for OXY-induced locomotor in B6JxB6NJ F2 cross_qvalueDESCRIPTION: Cis-eQTLs associated with peak distal chromosome 1 marker for oxycodone (OXY)-induced locomotor activity (rs51237371; 181,318,003 bp). We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. Analysis was conducted using limma with default TMM normalization and VOOM transformation (Law et al. 2014; Ritchie et al. 2015). To account for the presence of replicates of each sample in the data, we used the duplicateCorrelation() function to estimate the within-sample correlation which we then included in the lmFit() function. An ANOVA test was conducted for gene expression, with Genotype as a fixed effect and Sex as a covariate. Gene-level tests were conducted using the Likelihood Ratio test. A false discovery rate of 5% was employed as the cut-off for statistical significance (Benjamini & Hochberg 1995). From supplementary table S4.
Tier IV
Mouse
22 Genes
GS410670
LABEL: Striatal cis-eQTLs assoc. rs33209545 for OXY withdrawal EPM in B6JxB6NJ F2 cross_pvalueDESCRIPTION: Chromosome 5 cis-eQTL transcripts showing peak association with the peak behavioral QTL EPM marker for EPM behaviors during spontaneous OXY withdrawal (rs33209545; chromosome 5: 59,833,642 bp). We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. Analysis was conducted using limma with default TMM normalization and VOOM transformation (Law et al. 2014; Ritchie et al. 2015). To account for the presence of replicates of each sample in the data, we used the duplicateCorrelation() function to estimate the within-sample correlation which we then included in the lmFit() function. An ANOVA test was conducted for gene expression, with Genotype as a fixed effect and Sex as a covariate. Gene-level tests were conducted using the Likelihood Ratio test. A false discovery rate of 5% was employed as the cut-off for statistical significance (Benjamini & Hochberg 1995). From supplementary table S6.
Tier IV
Mouse
23 Genes
GS410671
LABEL: Striatal cis-eQTLs assoc. rs33209545 for OXY withdrawal EPM in B6JxB6NJ F2 cross_qvalueDESCRIPTION: Chromosome 5 cis-eQTL transcripts showing peak association with the peak behavioral QTL EPM marker for EPM behaviors during spontaneous OXY withdrawal (rs33209545; chromosome 5: 59,833,642 bp). We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. Analysis was conducted using limma with default TMM normalization and VOOM transformation (Law et al. 2014; Ritchie et al. 2015). To account for the presence of replicates of each sample in the data, we used the duplicateCorrelation() function to estimate the within-sample correlation which we then included in the lmFit() function. An ANOVA test was conducted for gene expression, with Genotype as a fixed effect and Sex as a covariate. Gene-level tests were conducted using the Likelihood Ratio test. A false discovery rate of 5% was employed as the cut-off for statistical significance (Benjamini & Hochberg 1995). From supplementary table S6.
Tier IV
Mouse
6 Genes
GS410672
LABEL: Striatal candidate genes assoc. chr5 rs33209545 EPM marker OXY withdrawal B6JxB6NJ F2 cross_pvalueDESCRIPTION: Chromosome 5 cis-eQTL transcripts showing peak association with the peak behavioral QTL EPM marker for EPM behaviors during spontaneous OXY withdrawal (rs33209545; chromosome 5: 59,833,642 bp). We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. Analysis was conducted using limma with default TMM normalization and VOOM transformation (Law et al. 2014; Ritchie et al. 2015). To account for the presence of replicates of each sample in the data, we used the duplicateCorrelation() function to estimate the within-sample correlation which we then included in the lmFit() function. An ANOVA test was conducted for gene expression, with Genotype as a fixed effect and Sex as a covariate. Gene-level tests were conducted using the Likelihood Ratio test. A false discovery rate of 5% was employed as the cut-off for statistical significance (Benjamini & Hochberg 1995). From supplementary table S6.
Tier IV
Mouse
6 Genes
GS410673
LABEL: Striatal candidate genes assoc. chr5 rs33209545 EPM marker OXY withdrawal B6JxB6NJ F2 cross_qvalueDESCRIPTION: Chromosome 5 cis-eQTL transcripts showing peak association with the peak behavioral QTL EPM marker for EPM behaviors during spontaneous OXY withdrawal (rs33209545; chromosome 5: 59,833,642 bp). We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. Analysis was conducted using limma with default TMM normalization and VOOM transformation (Law et al. 2014; Ritchie et al. 2015). To account for the presence of replicates of each sample in the data, we used the duplicateCorrelation() function to estimate the within-sample correlation which we then included in the lmFit() function. An ANOVA test was conducted for gene expression, with Genotype as a fixed effect and Sex as a covariate. Gene-level tests were conducted using the Likelihood Ratio test. A false discovery rate of 5% was employed as the cut-off for statistical significance (Benjamini & Hochberg 1995). From supplementary table S6.
Tier IV
Mouse
9 Genes
GS410674
LABEL: Chr1 eQTL OXY D2 locomotor distance (m) predicters B6JxB6NJ F2 cross_logFCDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY locomotor withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
9 Genes
GS410675
LABEL: Chr1 eQTL OXY D2 locomotor distance (m) predicters B6JxB6NJ F2 cross_logFCDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY locomotor withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
9 Genes
GS410676
LABEL: Chr1 eQTL OXY D2 locomotor distance (m) predicters B6JxB6NJ F2 cross_logFCDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY locomotor withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
10 Genes
GS410677
LABEL: Chr1 eQTL OXY D2 locomotor distance (m) predicters B6JxB6NJ F2 cross_pvalueDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY locomotor withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
11 Genes
GS410678
LABEL: Chr1 eQTL OXY D2 locomotor distance (m) predicters B6JxB6NJ F2 cross_qvalueDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY locomotor withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
11 Genes
GS410679
LABEL: Chr1 eQTL OXY D2 locomotor rotations predicters B6JxB6NJ F2 cross_logFCDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY locomotor withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
8 Genes
GS410680
LABEL: Chr1 eQTL OXY D2 locomotor rotations predicters B6JxB6NJ F2 cross_pvalueDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY locomotor withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
8 Genes
GS410681
LABEL: Chr1 eQTL OXY D2 locomotor rotations predicters B6JxB6NJ F2 cross_qvalueDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY locomotor withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
13 Genes
GS410682
LABEL: Chr1 eQTL OXY D2 locomotor spins predicters B6JxB6NJ F2 cross_logFCDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY locomotor withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
8 Genes
GS410683
LABEL: Chr1 eQTL OXY D2 locomotor spins predicters B6JxB6NJ F2 cross_pvalueDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY locomotor withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
15 Genes
GS410684
LABEL: Chr1 eQTL OXY D2 locomotor spins predicters B6JxB6NJ F2 cross_qvalueDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY locomotor withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
16 Genes
GS410685
LABEL: Chr1 eQTL OXY D4 locomotor distance (m) predicters B6JxB6NJ F2 cross_logFCDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY locomotor withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
1 Genes
GS410686
LABEL: Chr1 eQTL OXY D4 locomotor distance (m) predicters B6JxB6NJ F2 cross_pvalueDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY locomotor withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
18 Genes
GS410687
LABEL: Chr1 eQTL OXY D4 locomotor distance (m) predicters B6JxB6NJ F2 cross_qvalueDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY locomotor withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
18 Genes
GS410688
LABEL: Chr1 eQTL OXY D4 locomotor rotations predicters B6JxB6NJ F2 cross_logFCDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY locomotor withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
8 Genes
GS410689
LABEL: Chr1 eQTL OXY D4 locomotor rotations predicters B6JxB6NJ F2 cross_pvalueDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY locomotor withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
20 Genes
GS410690
LABEL: Chr1 eQTL OXY D4 locomotor rotations predicters B6JxB6NJ F2 cross_qvalueDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY locomotor withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
21 Genes
GS410691
LABEL: Chr1 eQTL OXY D4 locomotor spins predicters B6JxB6NJ F2 cross_logFCDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY locomotor withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
22 Genes
GS410692
LABEL: Chr1 eQTL OXY D4 locomotor spins predicters B6JxB6NJ F2 cross_pvalueDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY locomotor withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
23 Genes
GS410693
LABEL: Chr1 eQTL OXY D4 locomotor spins predicters B6JxB6NJ F2 cross_qvalueDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY locomotor withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
23 Genes
GS410694
LABEL: Chr1 eQTL OXY withdrawal EPM OA entries predicters B6JxB6NJ F2 cross_logFCDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY EPM withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
23 Genes
GS410695
LABEL: Chr1 eQTL OXY withdrawal EPM OA entries predicters B6JxB6NJ F2 cross_pvalueDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY EPM withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
24 Genes
GS410696
LABEL: Chr1 eQTL OXY withdrawal EPM OA entries predicters B6JxB6NJ F2 cross_qvalueDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY EPM withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
25 Genes
GS410697
LABEL: Chr1 eQTL OXY withdrawal EPM OA dist. predicters B6JxB6NJ F2 cross_logFCDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY EPM withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
26 Genes
GS410698
LABEL: Chr1 eQTL OXY withdrawal EPM OA dist. predicters B6JxB6NJ F2 cross_pvalueDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY EPM withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
27 Genes
GS410699
LABEL: Chr1 eQTL OXY withdrawal EPM OA dist. predicters B6JxB6NJ F2 cross_qvalueDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY EPM withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
28 Genes
GS410700
LABEL: Chr1 eQTL OXY withdrawal EPM OA % time predicters B6JxB6NJ F2 cross_logFCDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY EPM withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
29 Genes
GS410701
LABEL: Chr1 eQTL OXY withdrawal EPM OA % time predicters B6JxB6NJ F2 cross_pvalueDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY EPM withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
30 Genes
GS410702
LABEL: Chr1 eQTL OXY withdrawal EPM OA % time predicters B6JxB6NJ F2 cross_qvalueDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY EPM withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
9 Genes
GS410703
LABEL: Chr1 eQTL OXY D4 locomotor distance (m) predicters B6JxB6NJ F2 cross_pvalueDESCRIPTION: Regression of chromosome 1 eQTL transcripts onto OXY locomotor withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. In addition to eQTL analysis, we used the limma package and lmfit() to fit a linear mixed model where we regressed transcript levels onto OXY behaviors to identify predictors. Read counts were normalized and log2-transformed using VOOM (Law et al. 2014). Transformed counts were then fit using a linear model using the limma package (Ritchie et al. 2015) and individually regressed normalized, transformed read counts of eQTL transcripts onto OXY locomotor traits (distance, rotations, and spins for both D2 and D4) and/or OXY EPM withdrawal traits [Open Arm Distance (m), Open Arm Entries (#), and Open Arm Time (%)]. Sequence Lane (random effects repeated measure) and Sex were included as covariates. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S5.
Tier IV
Mouse
17 Genes
GS410704
LABEL: Chr5 eQTL OXY withdrawal EPM OA dist. (m) predicters B6JxB6NJ F2 cross_logFCDESCRIPTION: Regression of chromosome 5 eQTL transcripts onto EPM OXY withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. To aid in prioritizing candidate genes within the chromosome 5 QTL interval, we also regressed transcript levels onto EPM behaviors. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S7.
Tier IV
Mouse
18 Genes
GS410705
LABEL: Chr5 eQTL OXY withdrawal EPM OA dist. (m) predicters B6JxB6NJ F2 cross_pvalueDESCRIPTION: Regression of chromosome 5 eQTL transcripts onto EPM OXY withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. To aid in prioritizing candidate genes within the chromosome 5 QTL interval, we also regressed transcript levels onto EPM behaviors. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S7.
Tier IV
Mouse
20 Genes
GS410706
LABEL: Chr5 eQTL OXY withdrawal EPM OA dist. (m) predicters B6JxB6NJ F2 cross_qvalueDESCRIPTION: Regression of chromosome 5 eQTL transcripts onto EPM OXY withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. To aid in prioritizing candidate genes within the chromosome 5 QTL interval, we also regressed transcript levels onto EPM behaviors. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S7.
Tier IV
Mouse
21 Genes
GS410707
LABEL: Chr5 eQTL OXY withdrawal EPM OA entries predicters B6JxB6NJ F2 cross_logFCDESCRIPTION: Regression of chromosome 5 eQTL transcripts onto EPM OXY withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. To aid in prioritizing candidate genes within the chromosome 5 QTL interval, we also regressed transcript levels onto EPM behaviors. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S7.
Tier IV
Mouse
22 Genes
GS410708
LABEL: Chr5 eQTL OXY withdrawal EPM OA entries predicters B6JxB6NJ F2 cross_pvalueDESCRIPTION: Regression of chromosome 5 eQTL transcripts onto EPM OXY withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. To aid in prioritizing candidate genes within the chromosome 5 QTL interval, we also regressed transcript levels onto EPM behaviors. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S7.
Tier IV
Mouse
23 Genes
GS410709
LABEL: Chr5 eQTL OXY withdrawal EPM OA entries predicters B6JxB6NJ F2 cross_qvalueDESCRIPTION: Regression of chromosome 5 eQTL transcripts onto EPM OXY withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. To aid in prioritizing candidate genes within the chromosome 5 QTL interval, we also regressed transcript levels onto EPM behaviors. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S7.
Tier IV
Mouse
24 Genes
GS410710
LABEL: Chr5 eQTL OXY withdrawal EPM OA % time predicters B6JxB6NJ F2 cross_logFCDESCRIPTION: Regression of chromosome 5 eQTL transcripts onto EPM OXY withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. To aid in prioritizing candidate genes within the chromosome 5 QTL interval, we also regressed transcript levels onto EPM behaviors. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S7.
Tier IV
Mouse
25 Genes
GS410711
LABEL: Chr5 eQTL OXY withdrawal EPM OA % time predicters B6JxB6NJ F2 cross_pvalueDESCRIPTION: Regression of chromosome 5 eQTL transcripts onto EPM OXY withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. To aid in prioritizing candidate genes within the chromosome 5 QTL interval, we also regressed transcript levels onto EPM behaviors. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S7.
Tier IV
Mouse
26 Genes
GS410712
LABEL: Chr5 eQTL OXY withdrawal EPM OA % time predicters B6JxB6NJ F2 cross_qvalueDESCRIPTION: Regression of chromosome 5 eQTL transcripts onto EPM OXY withdrawal traits. We mapped the genetic basis of OXY behavioral sensitivity and spontaneous withdrawal in a B6J×B6NJ‐F2 reduced complexity cross (RCC). Upon identifying a major distal chromosome 1 QTL for oxycodone locomotion and withdrawal, we implemented an efficient fine mapping strategy using recombinant lines within the QTL interval, and resolved a 2.45‐Mb region. We then sourced a historical striatal expression QTL dataset from the same genetic cross to home in on functionally plausible candidate genes. Finally, we conducted immunoblot analysis of eQTL genes within a recombinant line capturing the behavioral QTL, providing further support for the candidacy of Atp1a2 and Kcnj9. The results provide multiple positional loci and highly plausible candidate genes underlying opioid behavioral sensitivity and withdrawal. 425 F2 mice (213 SAL, 212 OXY) were phenotyped in the OXY locomotor/CPP protocol during Weeks 1 and 2 (Fig.2A). F2 mice were trained in a two‐chamber unbiased CPP protocol over nine days (D), with initial preference (D1, SAL i.p.), two alternating pairings of OXY (1.25 mg/kg, i.p.) and SAL (i.p.), separated by 48h (D2‐D5), a consolidation period (D6‐D7), a drug‐free CPP test following SAL (i.p.) (D8), and a drug‐induced CPP test (D9) following either SAL (i.p.) in the SAL group or OXY (1.25 mg/kg, i.p.) in the OXY group. A subset (118 SAL, 118 OXY) went on to receive a high-dose, multi-week OXY regimen over Weeks 3 and 4 (Fig.2A). For week 3, mice were injected once daily with either SAL (i.p.) or OXY (20mg/kg, i.p.) on Monday through Thursday at 1600h. Sixteen hours later on Friday, the majority of these 236 F2 mice (160F2 mice total: 77F, 83M) were tested for baseline nociceptive sensitivity on the 52.5°C hot plate assay and then assessed for OXY‐induced antinociception (5mg/kg, i.p.) at 30min post‐OXY (see Data S1). The remaining 76 F2 mice (37F, 39M) received the same OXY regimen during Week 3 but were not exposed to hot plate testing. For Week 4, we continued injecting all 236 F2 mice (118 SAL, 118 OXY) once daily with SAL (i.p.) or OXY (20mg/kg, i.p.) for four days. On Day 5, 16h post‐injection, mice were tested for anxiety‐like behavior in the elevated plus maze (EPM). Striatum punches were collected from 23 OXY-trained F2 mice at 24 h after behavioral testing on the EPM. Libraries were prepared according to Illumina's detailed instructions accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The purified DNA was captured on an Illumina flow cell for cluster generation and sample libraries were sequenced at 23 samples per lane over 5 lanes (technical replicates) on the Illumina HiSeq 4000 machine, yielding an average of 69.4 million total reads per sample. We aligned FASTQ files to the mm38 genome via TopHat (Trapnell et al. 2012) and used the Ensembl sequence and genome annotation. We used featureCounts for read alignment. Exons with low expression (less than 10 reads total across all 115 count files) were removed. A a cis-eQTL was liberally defined as any transcript with a genome-wide significant association between expression and a polymorphic marker that was within 70 Mb of a SNP, given the large linkage disequilibrium in a lowly recombinant F2 cross and given that this was the largest distance between any two SNP markers. To aid in prioritizing candidate genes within the chromosome 5 QTL interval, we also regressed transcript levels onto EPM behaviors. An FDR-adjusted p-value of p<0.05 was employed to identify significant transcripts as predictors of behavior (Benjamini & Hochberg 1995). From supplementary table S7.
GeneWeaver